Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Sun Yat-sen University
Servier
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Sun Yat-sen University
Sun Yat-sen University
Genmab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Coherus Oncology, Inc.
NRG Oncology
Sun Yat-sen University
First Affiliated Hospital of Guangxi Medical University
Sun Yat-sen University
Hoffmann-La Roche
Sun Yat-sen University
Sun Yat-sen University
Shanghai Miracogen Inc.
Sun Yat-sen University
University of Southern California
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National University Hospital, Singapore
The University of Hong Kong
Sun Yat-sen University
Merck Sharp & Dohme LLC
Sun Yat-sen University
Sun Yat-sen University
Eye & ENT Hospital of Fudan University
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NGM Biopharmaceuticals, Inc
Sun Yat-sen University
Sun Yat-sen University
Akeso
Fudan University
Shanghai JMT-Bio Inc.
Zhejiang Cancer Hospital
Akeso
Sun Yat-sen University
City of Hope Medical Center
MediLink Therapeutics (Suzhou) Co., Ltd.
BeiGene
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Cyteir Therapeutics, Inc.
Sun Yat-sen University
West China Hospital
University of Malaya